Last reviewed · How we verify
Any FDA approved antipsychotic agent
Any FDA approved antipsychotic agent is a Antipsychotic (dopamine antagonist) Small molecule drug developed by Vanguard Research Group. It is currently FDA-approved for Schizophrenia, Bipolar disorder (acute mania and maintenance), Psychotic disorders.
FDA-approved antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
FDA-approved antipsychotics block dopamine and/or serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Psychotic disorders.
At a glance
| Generic name | Any FDA approved antipsychotic agent |
|---|---|
| Sponsor | Vanguard Research Group |
| Drug class | Antipsychotic (dopamine antagonist) |
| Target | Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Antipsychotics work primarily by antagonizing dopamine D2 receptors, which reduces excessive dopaminergic signaling implicated in psychosis. Many also block serotonin 5-HT2A receptors and other targets, contributing to efficacy across psychotic and mood disorders. The specific receptor profile varies by agent (typical vs. atypical antipsychotics).
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Psychotic disorders
- Agitation associated with dementia or delirium
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Weight gain
- Metabolic syndrome (hyperglycemia, dyslipidemia)
- Prolactin elevation (galactorrhea, sexual dysfunction)
- Sedation
- Orthostatic hypotension
- QT prolongation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Any FDA approved antipsychotic agent CI brief — competitive landscape report
- Any FDA approved antipsychotic agent updates RSS · CI watch RSS
- Vanguard Research Group portfolio CI
Frequently asked questions about Any FDA approved antipsychotic agent
What is Any FDA approved antipsychotic agent?
How does Any FDA approved antipsychotic agent work?
What is Any FDA approved antipsychotic agent used for?
Who makes Any FDA approved antipsychotic agent?
What drug class is Any FDA approved antipsychotic agent in?
What development phase is Any FDA approved antipsychotic agent in?
What are the side effects of Any FDA approved antipsychotic agent?
What does Any FDA approved antipsychotic agent target?
Related
- Drug class: All Antipsychotic (dopamine antagonist) drugs
- Target: All drugs targeting Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)
- Manufacturer: Vanguard Research Group — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar disorder (acute mania and maintenance)
- Indication: Drugs for Psychotic disorders
- Compare: Any FDA approved antipsychotic agent vs similar drugs
- Pricing: Any FDA approved antipsychotic agent cost, discount & access